Pfizer Inc. (NYSE:PFE) Shares Purchased by Toronto Dominion Bank

Toronto Dominion Bank raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 62.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,695,774 shares of the biopharmaceutical company's stock after acquiring an additional 1,802,005 shares during the quarter. Toronto Dominion Bank owned 0.08% of Pfizer worth $124,578,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Park Avenue Securities LLC increased its holdings in shares of Pfizer by 11.4% during the fourth quarter. Park Avenue Securities LLC now owns 106,050 shares of the biopharmaceutical company's stock valued at $2,814,000 after purchasing an additional 10,824 shares during the period. Tallon Kerry Patrick acquired a new position in shares of Pfizer during the fourth quarter valued at $509,000. Cohen Investment Advisors LLC increased its holdings in shares of Pfizer by 4.5% during the fourth quarter. Cohen Investment Advisors LLC now owns 78,409 shares of the biopharmaceutical company's stock valued at $2,080,000 after purchasing an additional 3,343 shares during the period. Werlinich Asset Management LLC increased its holdings in shares of Pfizer by 2.6% during the fourth quarter. Werlinich Asset Management LLC now owns 92,735 shares of the biopharmaceutical company's stock valued at $2,450,000 after purchasing an additional 2,350 shares during the period. Finally, Edge Wealth Management LLC increased its holdings in shares of Pfizer by 6.2% during the fourth quarter. Edge Wealth Management LLC now owns 8,517 shares of the biopharmaceutical company's stock valued at $226,000 after purchasing an additional 500 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PFE. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Up 1.0%

NYSE:PFE opened at $22.83 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm has a market capitalization of $129.77 billion, a price-to-earnings ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The stock has a fifty day simple moving average of $23.65 and a 200 day simple moving average of $25.36.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the company posted $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer's payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.